Announcements Trials
Browse Landscape

Phase

Phase NA 17Phase 2 8Phase 1/2 5Phase 1 3Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 39Unknown 13Terminated 7Active not recruiting 6Recruiting 5Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 41Carcinoma, Non-Small-Cell Lung 27Colorectal Neoplasms 17Neoplasms 13Prostatic Neoplasms 11Nasopharyngeal Carcinoma 11Lung Neoplasms 11Carcinoma, Hepatocellular 11Multiple Myeloma 9Leukemia, Myeloid, Acute 9Stomach Neoplasms 8Small Cell Lung Carcinoma 8Ovarian Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Rectal Neoplasms 7Esophageal Neoplasms 7Triple Negative Breast Neoplasms 6Pancreatic Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 6Neoplasm Metastasis 6Esophageal Squamous Cell Carcinoma 6Uterine Cervical Neoplasms 5Recurrence 5Glioblastoma 5Colonic Neoplasms 5Carcinoma, Renal Cell 5Brain Neoplasms 5Adenocarcinoma 5Urinary Bladder Neoplasms 4Lymphoma, Follicular 4

Interventions

atezolizumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × Liver Neoplasms × Clear all
NCT06680258 2025-09-03

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

Tempest Therapeutics

Phase 3 Not yet recruiting
740 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡